Teva enhances CNS portfolio with Auspex acquisition
Israel’s Teva Pharmaceutical Industries Ltd has agreed to acquire U.S. biopharmaceutical firm Auspex Pharmaceuticals Inc, boosting its range of treatments for the central nervous system (CNS).
Israel’s Teva Pharmaceutical Industries Ltd has agreed to acquire U.S. biopharmaceutical firm Auspex Pharmaceuticals Inc, boosting its range of treatments for the central nervous system (CNS).
Pennsylvania-based NuPathe specializes in therapeutics for diseases of the central nervous system (CNS), including neurological and psychiatric disorders.